ArticleOncotarget2016
Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review.European journal of nuclear medicine and molecular imaging · 2019Pooled it
- Beyond the Biopsy: Imaging Frontiers in Cardiac Sarcoidosis.Cardiology research and practice · 2026Review
- A Comprehensive Review of SSTR-Based Spect and Pet Imaging in Chronic Inflammatory and Immune-Mediated Diseases.Journal of clinical medicine · 2025Review
- Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging.Npj imaging · 2025Review
- Application of Radionuclide Myocardial Imaging in the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction.Reviews in cardiovascular medicine · 2025Review
- A scoping review on potential of novel developments in fever of unknown origin and inflammation of unknown origin: long-axial-field-of-view positron emission tomography/computed tomography and novel radiotracers.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2025Article
- Emerging PET-radiotracers in cardiovascular, neuro-inflammation, lung and rheumatological diseases: a narrative review.EJNMMI reports · 2025Review
- Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Diagnostic yield of a novel tracer 68Ga-citrate in sarcoidosis patients.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Histopathological Evaluation of Somatostatin Receptor 2 Expression in Myocarditis-Rationale for the Diagnostic Use of Somatostatin Receptor Imaging.Diagnostics (Basel, Switzerland) · 2024Article
- Vascular adhesion protein-1-targeted PET imaging in autoimmune myocarditis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- The clinical value of quantitative cardiovascular molecular imaging: a step towards precision medicine.The British journal of radiology · 2023Review
- Phenotyping heart failure by nuclear imaging of myocardial perfusion, metabolism, and molecular targets.European heart journal. Cardiovascular Imaging · 2023Review
- Reference myocardial uptake values on somatostatin receptor-targeted PET: not yet in preference to visual assessment.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Potential clinical utility ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Semiquantitative evaluation ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Detection of acute myocarditis by ECG-triggered PET imaging of somatostatin receptors compared to cardiac magnetic resonance: preliminary results.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach.Frontiers in nuclear medicine · 2023Review
- Potential novel imaging targets of inflammation in cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of cardiac sarcoidosis is often challenging. Whereas cardiac magnetic resonance imaging (CMR) and positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) are most commonly used to evaluate patients, PET/CT using radiolabeled somatostatin receptor (SSTR) ligands for visualization of inflammation might represent a more specific alternative. This study aimed to investigate the feasibility of SSTR-PET/CT for detecting cardiac sarcoidosis in comparison to CMR.15 patients (6 males, 9 females) with sarcoidosis and suspicion on cardiac involvement underwent SSTR-PET/CT imaging and CMR. Images were visually scored. The AHA 17-segment model of the left myocardium was used for localization and comparison of inflamed myocardium for both imaging modalities. In semi-quantitative analysis, mean (SUVmean) and maximum standardized uptake values (SUVmax) of affected myocardium were calculated and compared with both remote myocardium and left ventricular (LV) cavity.SSTR-PET was positive in 7/15, CMR in 10/15 patients. Of the 3 CMR+/PET- subjects, one patient with minor involvement (<25% of wall thickness in CMR) was missed by PET. The remaining two CMR+/PET- patients displayed no adverse cardiac events during follow-up.In the 17-segment model, PET/CT yielded 27 and CMR 29 positive segments. Overall concordance of the 2 modalities was 96.1% (245/255 segments analyzed). SUVmean and SUVmax in inflamed areas were 2.0±1.2 and 2.6±1.2, respectively. The lesion-to-remote myocardium and lesion-to-LV cavity ratios were 1.8±0.2 and 1.9±0.2 for SUVmean and 2.0±0.3 and 1.7±0.3 for SUVmax, respectively.Detection of cardiac sarcoidosis by SSTR-PET/CT is feasible. Our data warrant further analysis in larger prospective series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.